{"id":20657,"date":"2026-02-07T13:42:57","date_gmt":"2026-02-07T12:42:57","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=20657"},"modified":"2026-05-04T16:55:04","modified_gmt":"2026-05-04T15:55:04","slug":"acmd-announces-decision-on-the-classification-of-ketamine","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2026\/02\/acmd-announces-decision-on-the-classification-of-ketamine\/","title":{"rendered":"ACMD announces decision on the classification of ketamine"},"content":{"rendered":"<div class=\"govuk-grid-row gem-print-columns-none translation-nav-header\">\n<div class=\"govuk-grid-column-two-thirds translation-nav-header__child\">\n<div class=\"gem-c-heading govuk-!-margin-bottom-0\" dir=\"ltr\"><\/div>\n<\/div>\n<\/div>\n<div class=\"govuk-grid-row gem-print-columns-none\">\n<div class=\"govuk-grid-column-two-thirds \">\n<div class=\"content-bottom-margin\">\n<div class=\"responsive-bottom-margin\">\n<figure class=\"gem-c-figure govuk-!-margin-bottom-8\" lang=\"en\"><figcaption class=\"gem-c-figure__figcaption\">\n<p class=\"gem-c-figure__figcaption-text\" style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">by the Advisory Council on the Misuse of Drugs (ACMD) &#8211; 28 January 2026<\/span><\/p>\n<\/figcaption><\/figure>\n<div class=\"gem-c-govspeak govuk-govspeak gem-c-govspeak--direction-ltr govuk-!-margin-bottom-0\" data-module=\"govspeak\" data-govspeak-module-started=\"true\">\n<div class=\"govspeak\">\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\"><strong>The\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0has\u00a0advised\u00a0the government ketamine should remain a class B controlled substance, but that police forces and health care professionals must receive greater support to better\u00a0identify,\u00a0prevent\u00a0and respond to ketamine\u2011related harms.<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">In January 2025, the government asked the\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0to review the prevalence and harms of the misuse of ketamine. After examining the latest evidence, engaging with people with lived or living experience with the substance, consulting stakeholders, and reviewing academic research, the\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0concluded ketamine should not be reclassified and should remain in class B.<\/span><\/p>\n<h2 id=\"findings-and-decisions\" style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">Findings and decisions<\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">In reaching its decision, the\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0noted that the acute harms of ketamine &#8211; such as toxicity and deaths &#8211; align with its current class B status.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">The\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0also expressed concern about the growing use of high\u2011dose ketamine &#8211; described in some cases as \u201cchronic\u201d- and the long\u2011term harms associated with it.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">However, as these harms were\u00a0established\u00a0in the 2013 ketamine assessment, the group focused its discussions on\u00a0identifying\u00a0new and emerging risks.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">The\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0report highlighted that many acute harms experienced by ketamine users are likely to be significantly influenced by using other drugs at the same time, and that reclassifying ketamine in isolation would unlikely reduce prevalence or misuse.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">Individuals with personal experience of ketamine use and harms who contributed to the review said they did not believe upgrading ketamine to class A would reduce its use. Health and social care professionals similarly, largely, voiced opposition to reclassification.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">Ultimately, the\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0concluded that a public health\u2011centred approach is essential for reducing ketamine-related harms. This approach requires co-ordinated action across public bodies, health services, and community organisations.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">The\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0Chair Professor David Wood said in relation to the report:<\/span><\/p>\n<blockquote>\n<p class=\"last-child\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">The\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u00a0report highlights the need for a \u2018whole system\u00a0approach\u2019 through its recommendations to tackle issues related to ketamine use, as no single recommendation is sufficient to do this alone.<\/span><\/p>\n<\/blockquote>\n<h2 id=\"recommendations\" style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">Recommendations\u00a0\u00a0<\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">The\u00a0<abbr title=\"Advisory Council on the Misuse of Drugs\">ACMD<\/abbr>\u2019s recommendations are outlined in full in\u00a0their report. This includes recommendations on classification, improving treatment of ketamine-related harms, international control, intelligence gathering, education and training, harm\u00a0reduction\u00a0and research.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: verdana, geneva, sans-serif; font-size: 10pt; color: #0000ff;\">Source: https:\/\/www.gov.uk\/government\/news\/acmd-announces-decision-on-the-classification-of-ketamine<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>by the Advisory Council on the Misuse of Drugs (ACMD) &#8211; 28 January 2026 The\u00a0ACMD\u00a0has\u00a0advised\u00a0the government ketamine should remain a class B controlled substance, but that police forces and health care professionals must receive greater support to better\u00a0identify,\u00a0prevent\u00a0and respond to ketamine\u2011related harms. In January 2025, the government asked the\u00a0ACMD\u00a0to review the prevalence and harms of [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[73,68,80,40,36,128],"tags":[],"class_list":["post-20657","post","type-post","status-publish","format-standard","hentry","category-addiction","category-drug-use-various-effects","category-ketamine","category-prevention-research","category-treatment-addiction","category-uk"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=20657"}],"version-history":[{"count":1,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20657\/revisions"}],"predecessor-version":[{"id":20658,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20657\/revisions\/20658"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=20657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=20657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=20657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}